Equities
  • Price (EUR)2.11
  • Today's Change-0.06 / -2.76%
  • Shares traded933.90k
  • 1 Year change-82.98%
  • Beta-3.1751
Data delayed at least 15 minutes, as of Jan 27 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.

  • Revenue in EUR (TTM)320.86m
  • Net income in EUR101.33m
  • Incorporated2006
  • Employees174.00
  • Location
    Novacyt SA13 avenue Morane SaulnierVELIZY VILLACOUBLAY 78140FranceFRA
  • Phone+33 139465104
  • Fax+33 130700532
  • Websitehttps://novacyt.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Spineguard SA4.80m-2.16m33.42m14.00--7.27--6.96-0.0915-0.09150.20030.15470.4811.956.88369,522.30-21.62-32.72-41.70-59.0373.3279.19-44.95-40.241.92-1.060.5273---28.95-5.23-296.13---19.31--
Pixium Vision SA2.64m-10.90m41.96m28.00--10.26--15.88-0.2498-0.24980.06050.06970.1931--502.7394,351.43-79.68-51.14-113.78-58.40100.0086.35-412.56-553.852.71-12.460.49--17.34-8.707.35---47.73--
Visiomed Group SA18.98m-5.15m57.66m26.00------3.04-0.2657-0.26571.02-0.17381.847.7868.14729,846.10-49.72-88.78---214.569.4133.62-27.04-130.930.4061-8.43----85.3711.7578.59---17.42--
Amplitude Surgical SA95.50m-14.10m99.40m443.00--1.6840.991.04-0.2949-0.29492.001.230.35091.1510.17215,580.10-5.39-4.40-6.33-5.0948.1848.56-15.36-12.631.30-0.43170.7207--8.173.400.6973---12.07--
Affluent Medical SAS0.00-14.88m101.54m----1.98-----0.8891-0.88910.002.83---------------------------5.770.2703------13.68------
Novacyt SA320.86m101.33m153.71m174.001.480.9261.490.4791.471.474.622.352.057.319.331,844,031.0064.6150.7383.2471.5560.1374.1631.5837.194.0258.950.02050.002,317.20112.093,973.15--14.42--
Carmat SA0.00-42.48m265.30m139.00--7.86-----3.45-3.450.002.200.00----0.00-58.90-71.39-69.94-85.87--------5.52-14.280.5441------13.33--51.40--
Bastide Le Confort Medical SA444.07m13.45m344.76m3.04k25.664.215.260.77641.831.8360.3611.140.82614.788.55146,124.702.672.413.693.4647.4047.603.232.780.81963.910.807917.8216.0418.2815.9713.3715.490.7577
Lumibird SA156.40m12.64m462.82m870.0029.012.7119.682.960.710.718.277.610.51481.445.22186,410.004.163.954.985.0460.1359.798.086.722.3111.440.34560.0014.4615.32-36.0821.5429.37--
Data as of Jan 27 2022. Currency figures normalised to Novacyt SA's reporting currency: Euro EUR

Institutional shareholders

5.16%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 12 Mar 20211.99m2.81%
J.O. Hambro Capital Management Ltd.as of 31 Dec 20211.06m1.49%
American Century Investment Management, Inc.as of 06 Jan 2022204.55k0.29%
Goldman Sachs Asset Management LPas of 28 Feb 2021122.07k0.17%
Lyxor International Asset Management SASas of 05 Jan 202298.48k0.14%
SSgA Funds Management, Inc.as of 06 Jan 202275.90k0.11%
FINEXIS SAas of 30 Jun 202061.23k0.09%
Quoniam Asset Management GmbHas of 31 Mar 202124.66k0.04%
Octopus Investments Ltd.as of 31 Dec 20219.30k0.01%
Inversis Gesti�n SGIIC SAas of 30 Sep 20214.89k0.01%
More ▼
Data from 31 Dec 2020 - 19 Jan 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.